PEG-Modified Interleukin-12 Reduces Toxicity and Extends Half-Life

The patent applies parameter changes by modifying the molecular weight and structure of IL-12 through PEGylation. The PEG-modified IL-12 has increased molecular weight and altered pharmacokinetic parameters, allowing for larger doses to be administered. This changes the dosage parameter from the original limited range to a higher effective range, achieving better therapeutic effect while maintaining reduced toxicity through the modified molecular characteristics.

The patent creates a composite material by chemically conjugating polyethylene glycol (PEG) with interleukin-12. This PEG-IL-12 conjugate combines the immunomodulatory properties of IL-12 with the stabilizing and immunogenicity-reducing properties of PEG. The composite structure allows the drug to maintain biological activity while reducing toxic side effects and immunogenicity, resolving the contradiction between efficacy and safety.

The patent changes the molecular parameter of IL-12 by PEGylation, which alters its pharmacokinetic profile. The PEG-modified IL-12 exhibits reduced immunogenicity and modified clearance rates, enabling administration at higher doses. This parameter change in molecular structure directly enables dose escalation while maintaining an acceptable safety profile, breaking the direct proportionality between dose increase and toxicity increase.

The PEG chain acts as an intermediary between the IL-12 molecule and the immune system. This intermediary reduces the direct interaction between native IL-12 epitopes and the immune system, thereby reducing immunogenicity and toxic side effects. The PEG spacer allows the IL-12 to maintain its biological function while being 'shielded' from causing excessive immune activation and toxicity, enabling higher effective doses.

The patent applies partial action by using PEGylation to achieve a moderate extension of half-life that is sufficient to reduce injection frequency from frequent (multiple times per week) to less frequent (once or twice per week). This partial modification provides just enough pharmacokinetic improvement to maintain effective blood concentrations with reduced dosing frequency, balancing treatment effectiveness with patient convenience without requiring excessive PEG chain lengths that might over-prolong half-life.

The patent changes the pharmacokinetic parameter of half-life through PEGylation. The modified IL-12 exhibits extended circulation half-life due to reduced renal clearance and protected proteolytic degradation. This parameter change in half-life directly reduces the dosing frequency requirement, allowing maintenance of effective blood concentrations with less frequent injections, thereby improving patient convenience while maintaining treatment effectiveness.

The patent changes the molecular weight and hydrodynamic radius parameters of IL-12 through PEGylation. These parameter changes result in altered pharmacokinetic behavior, including extended half-life and reduced clearance rate. The modified molecular parameters enable the drug to maintain stable blood concentrations over longer periods, reducing the violent fluctuations seen with native IL-12 at low doses, while still allowing administration at lower effective doses with reduced toxicity.

The PEG chain serves as an intermediary that stabilizes the pharmacokinetic profile of IL-12. It provides a steric barrier that protects the protein from rapid clearance and degradation, creating a more stable and predictable blood concentration profile. This intermediary effect smooths out the violent concentration fluctuations characteristic of low-dose native IL-12 therapy, maintaining therapeutic levels more consistently between doses.